DACS
PFE icon

Dymon Asia Capital (Singapore)’s Pfizer PFE Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,600
Closed -$838K – 158
2024
Q4 		$838K Sell
31,600
-18,400
-37% -$499K 0.19% 84
2024
Q3 		$1.45M Buy
+50,000
New +$1.46M 0.39% 54

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s PFE Position: Q1 2025 in Review

Dymon Asia Capital (Singapore) sold out of Pfizer (PFE) in Q1 2025, closing a stake of 31,600 shares — an estimated $838K sold.

Dymon Asia Capital (Singapore) first reported a position in PFE in Q3 2024 and held it in 2 quarters. The position peaked at $1.45M in Q3 2024. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Dymon Asia Capital (Singapore) reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 31,600 Pfizer shares in Q1 2025, an estimated $838K.
  • Dymon Asia Capital (Singapore) first reported a position in Pfizer in Q3 2024 and held it in 2 quarters.
  • Dymon Asia Capital (Singapore)'s Pfizer position peaked at $1.45M in Q3 2024.
  • 2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.